| GTO ID | GTC4012 |
| Trial ID | NCT02028117 |
| Disease | Ovarian Cancer |
| Altered gene | E1A|E1B |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | DNA oncolytic virus |
| Treatment | ColoAd1|Enadenotucirev |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Clinical Study Of Enadenotucirev: Dose Finding and Proof of Concept in Platinum-Resistant Epithelial Ovarian Cancer |
| Year | 2014 |
| Country | Spain|United Kingdom |
| Company sponsor | Akamis Bio |
| Other ID(s) | ColoAd1-2001 |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||||||
|
|||||||||